All Stories

  1. Cholinesterase Inhibition and Anticancer Properties of [4-(Benzyloxy) phenyl]{Methylidene}hydrazinylidene]-1,3-dihydro-2H-Indol-2-ones Using Swiss Target-guided Prediction
  2. Inhibiting Monoamine Oxidase in CNS and CVS would be a Promising Approach to Mitigating Cardiovascular Complications in Neurodegenerative Disorders
  3. Molecular Docking, Microwave-Assisted Synthesis, Characterization and Pharmacological Evaluation of 2,4,5-trisubstituted Imidazole’s
  4. In Silico Approaches to Naturally Existing Chalcones and Flavonoids on Mao Inhibitory Action: A Boon to CNS Drug Discovery
  5. Development of 2D, 3D-QSAR and Pharmacophore Modeling of Chalcones for the Inhibition of Monoamine Oxidase B
  6. The Role of Mitochondrial Genes in Neurodegenerative Disorders
  7. Current Perspective of COVID-19 on Neurology: A Mechanistic Insight
  8. Nanotechnology-based Approaches and Investigational Therapeutics against COVID-19
  9. Neuroprotective Effects of Ellagic Acid in Alzheimer's Disease: Focus on Underlying Molecular Mechanisms of Therapeutic Potential
  10. Fascinating Chemopreventive Story of Wogonin: A Chance to Hit on the Head in Cancer Treatment
  11. Dysregulation of the Gut-Brain Axis, Dysbiosis and Influence of Numerous Factors on Gut Microbiota Associated Parkinson’s Disease
  12. Exploring the Role of Aggregated Proteomes in the Pathogenesis of Alzheimer’s Disease
  13. New Aspects of Monoamine Oxidase B Inhibitors: The Key Role of Halogens to Open the Golden Door
  14. A Comprehensive Review of Monoamine Oxidase-A Inhibitors in their Syntheses and Potencies
  15. Privileged Pharmacophore of FDA Approved Drugs in Combination with Chalcone Framework: A New Hope for Alzheimer’s Treatment
  16. Exploring the Multifunctional Neuroprotective Promise of Rasagiline Derivatives for Multi-Dysfunctional Alzheimer’s Disease
  17. Emerging Promise of Immunotherapy for Alzheimer’s Disease: A New Hope for the Development of Alzheimer’s Vaccine
  18. An Environment-friendly Synthesis of Piperonal Chalcones and Their Cytotoxic and Antioxidant Evaluation
  19. Ethyl Acetohydroxamate Incorporated Chalcones: Unveiling a Novel Class of Chalcones for Multitarget Monoamine Oxidase-B Inhibitors Against Alzheimer’s Disease
  20. Anti-inflammatory effect of synthesized indole-based chalcone (2E)-3-(4-bromophenyl)-1-(1H-indol-3-yl) prop-2-en-1-one: an in vitro and in vivo studies
  21. Studies on the interaction between HSA and new halogenated metformin derivatives: influence of lipophilic groups in the binding ability
  22. Cholinesterase Inhibitory Activities of Selected Halogenated Thiophene Chalcones
  23. Dual Acting Isatin-heterocyclic Hybrids: Recent Highlights as Promising Pharmacological Agents
  24. Virtual Combinatorial Library Design, Synthesis and In vitro Anticancer Assessment of -2-Amino-3-Cyanopyridine Derivatives
  25. Structural Exploration of Synthetic Chromones as Selective MAO-B Inhibitors: A Mini Review
  26. Synthetic Approaches to Various Class of Topoisomerase II Inhibitors
  27. Novel HDAC8 inhibitors: A multi-computational approach
  28. Monoamine Oxidase-A: A Valid Target for the Management of Depression
  29. Pyrazoline: A Promising Scaffold for the Inhibition of Monoamine Oxidase
  30. Ligand based Drug Design of New Heterocyclic Imines of GABA Analogues: A Molecular Docking Approach for the Discovery of New GABA-AT Inhibitors
  31. Discovery of Camptothecin Based Topoisomerase I Inhibitors: Identification Using an Atom Based 3D-QSAR, Pharmacophore Modeling, Virtual Screening and Molecular Docking Approach
  32. Monoamine Oxidase Inhibitors: Perspective Design for the Treatment of Depression and Neurological Disorders
  33. Monoamine Oxidase Inhibitory Action of Chalcones: A Mini Review
  34. Flavonoids: An Outstanding Structural Core for the Inhibition of Xanthine Oxidase Enzyme
  35. Development of Fluorinated Thienylchalcones as Monoamine Oxidase-B Inhibitors: Design, Synthesis, Biological Evaluation and Molecular Docking Studies
  36. Development of fluorinated methoxylated chalcones as selective monoamine oxidase-B inhibitors: Synthesis, biochemistry and molecular docking studies
  37. Hydrazones as a Privileged Structural Linker in Antitubercular Agents: A Review
  38. Molecular Hybridization and Preclinical Evaluation of Imines From Para-substituted 4-phenyl 2-amino Thiazole Incorporated with Isatin Analogues as Antitubercular Agents
  39. Determination of in vitro free radical scavenging and antiproliferative effect of Pennisetum alopecuroides on cultured A549 human lung cancer cells
  40. Plant Secondary Metabolites- Potent Inhibitors of Monoamine Oxidase Isoforms
  41. Molecular Recognisation of 3a, 4-Dihydro-3-H-Indeno [1, 2-C] Pyrazole-2- Carboxamide/Carbothioamide Anticonvulsant Analogues Towards GABA-Aminotransferase- An in Silico Approach
  42. Isolation of a bioactive flavonoid from Spilanthes calva D.C. in vitro xanthine oxidase assay and in silico study
  43. Proposed interaction of some novel antidepressant pyrazolines against monoamine oxidase isoforms. Molecular docking studies and PASS assisted in silico approach
  44. Synthesis, in silico preclinical evaluation, antidepressant potential of 5-substituted phenyl-3-(thiophen-2-yl)-4,5-dihydro-1h-pyrazole-1-carboxamides
  45. Heteroaryl chalcones: Mini review about their therapeutic voyage
  46. Isolation and molecular recognization of 6-prenyl apigenin towards MAO-A as the active principle of seeds of Achyranthes aspera
  47. Pyrazoline: A Promising Scaffold for the Inhibition of Monoamine Oxidase
  48. Hypnotic Profile of Imines from Benzimidazole Chalcones: Mechanism of Synthesis, DFT Studies and in silico Screening
  49. Design of 1-(furan-2-yl)-N-(5-substituted phenyl-1, 3, 4-thiadiazol-2-yl) methanimine derivatives as Enoyl-ACP reductase inhibitors: Synthesis, molecular docking studies and anti-tubercular activity
  50. Discovery of some novel imines of 2-amino, 5-thio, 1,3,4-thiadiazole as mucomembranous protector. Synthesis, anti-oxidant activity and in silico PASS approach
  51. Synthesis and PASS-assisted in silico approach of some novel 2-substituted benzimidazole bearing a pyrimidine-2, 4, 6(trione) system as mucomembranous protector
  52. Antitumour activity of 5-[(2E)-1-(1H-benzimidazol-2-yl)-3-substituted phenylprop-2-en-1-ylidene] pyrimidine-2,4,6(1H,3H,5H)-triones against Dalton’s ascitic lymphoma in mice
  53. Development of novel (1-H) benzimidazole bearing pyrimidine-trione based MAO-A inhibitors: Synthesis, docking studies and antidepressant activity